Apogenix GmbH
, develops drugs that are based on the targeted modulation of CD95 and Interleukin-4 receptor mediated signaling pathways... Read moreApogenix GmbH
, develops drugs that are based on the targeted modulation of CD95 and Interleukin-4 receptor mediated signaling pathways... Read more
News
Jun 01, 2023
FinanzNachrichten
Apogenix GmbH: EQS-News: Apogenix AG: Apogenix' new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
Mar 27, 2023
centralcharts
Press Release: Apogenix GmbH : EQS-News: Apogenix' Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme
Dec 14, 2022
centralcharts
Press Release: Apogenix GmbH : EQS-News: Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
Oct 20, 2022
Clinical Trials Arena
Apogenix GmbH: Apogenix's asunercept shown to offer benefits in Phase II Covid-19 trial
Dec 09, 2021
European Biotechnology
Apogenix GmbH: Apogenix gets 25.8m cash injection for asunercept
Dec 09, 2021
MarketScreener
Apogenix GmbH: Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19
Dec 22, 2020
MarketScreener
Apogenix GmbH: PRESS RELEASE : Apogenix AG: COVID-19 targeted treatment trial launched in Vienna
Oct 13, 2020
MarketScreener
Apogenix: Apogenix : Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial
Jul 28, 2020
MarketScreener
Apogenix: Apogenix : to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients
Jun 17, 2020
MarketScreener
Apogenix: Apogenix : to Present at AACR Virtual Annual Meeting II
Apogenix GmbH Competitors
1
2
3
4
5
6
7
8
9
10